Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07010705 · ClinicalTrials.gov registry record

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

A clinical trial of Healthy and Huntington Disease, sponsored by University of Rochester.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT07010705: Recruiting study of Healthy and Huntington Disease, sponsored by University of Rochester.

NCT07010705 is a study of Healthy and Huntington Disease that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 100 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07010705, a study of Healthy and Huntington Disease, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.

Primary Outcome

Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

Conditions Studied

Healthy Huntington Disease

Interventions

  • DEVICE ActiGraph LEAP
  • DEVICE Axivity AX6

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-20
Est. Completion 2026-09-30
University of Rochester

636 total trials

What NCT07010705 shows while recruiting

NCT07010705 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which ActiGraph LEAP is the first listed.

NCT07010705 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07010705 about?

NCT07010705 is a clinical study titled "Digital Measures for Clinical Trial Endpoints in Huntington's Disease". MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators ...

What is the current status of trial NCT07010705?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-06-20. Estimated completion is 2026-09-30.

What conditions does trial NCT07010705 study?

This clinical trial studies the following conditions: Healthy, Huntington Disease.

What interventions are being tested in trial NCT07010705?

The interventions under investigation include: ActiGraph LEAP (DEVICE), Axivity AX6 (DEVICE).

Who is sponsoring clinical trial NCT07010705?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07010705 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07010705's enrollment target sits among peer trials

100 219th of 1090 higher than 851 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07010705

Source: ClinicalTrials.gov NCT07010705, the US trial registry maintained by the National Library of Medicine. NCT07010705 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.